Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of TR115 in relapsed and/or refractory peripheral T/NK-cell lymphoma
CTR20262043Phase 3Active
- Sponsor
- Tarapeutics Science Inc
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TR115 in peripheral T-cell lymphoma (PTCL), sponsored by Tarapeutics Science Inc. Started May 2026; status: active.
02
Drugs
TR115
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20262043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262043.